Pre-pregnancy Genetic Testing Market - Industry Analysis, Market Size, Share, Trends, Growth And Forecast 2022 - 2027

Report Code: HCR 0652 Report Format: PDF + Excel

Pre-pregnancy Genetic Testing Market Overview

The Pre-pregnancy Genetic Testing Market size is estimated to reach $262.3 million by 2027. Furthermore, it is poised to grow at a CAGR of 5.2% over the forecast period of 2022-2027. Panels and kits are both available for genetic testing. Blood samples are taken from patients and passed through laboratory machines utilizing several types of test kits for genotyping. Pre-pregnancy genetic testing aids in the early detection of a problem with an unborn child, such as bone abnormalities, before or during pregnancy. It's done to learn about birth problems linked to genetic disorders, including syndromes and diseases like anaemia and cystic fibrosis, among others. Hereditary abnormalities can lead to major consequences later in life, such as mental impairment, strokes, loss of motion, cardiac issues, and so on. Pre-pregnancy genetic testing allows gynecologists' to identify such disorders and set up a treatment procedure by looking at the embryo's hereditary makeup. Pre-pregnancy genetic testing can detect chromosomal abnormalities such as 18 (Edwards disorder) and trisomy 13 (Patau disorder), which are among the conditions that can be detected. As more expecting women become aware of the benefits of undergoing hereditary testing at the appropriate time resulting in the pre-pregnancy genetic testing industry expansion. This enables parents to mentally and financially prepare for the support of a kid with special needs. The global pre-pregnancy genetic testing market has benefited from the increasing advancement in technology in the medical and healthcare fields, as well as extensive research into hereditary qualities to understand the causal connections between phenotypical features and the medical field, by making the testing forms more solid, proficient, and advantageous. As a result of technological developments in genetic testing techniques, diagnostic tests, and equipment, the testing methodology has become more convenient and reliable. The increased availability of cutting-edge pre-pregnancy genetic and cordocentesis testing has been especially important for the global industry since the demand for modern pre-pregnancy genetic testing has increased owing to a growing preference for minimally invasive medical procedures. The rising healthcare expenditure in emerging economies is another factor that could have a substantial impact on pre-pregnancy genetic testing market growth.

Report Coverage:

The report: “Pre-pregnancy Genetic Testing Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Pre-pregnancy Genetic Testing Industry.

By Test Type - Diagnostic Test, Chorionic Villi Sampling (CVS), Transabdominal CVS, Transvaginal CVS, Amniocentesis, Placental Biopsy, Cordocentesis, Foetal Biopsy, Screening Test, Carrier Screening, Sequential Screening, and Maternal Serum Quad Screening.
By End UsersHospitals, Clinics, and Diagnostic Centers.
By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America), and Rest of the World (the Middle East, and Africa).

Key Takeaways:

  • Geographically, the North America segment will dominate the market pertaining to the fact that North America's market has been spurred by modern healthcare infrastructure and customers' high spending power, which allows them to access pricey medical services.
  • During the forecast period 2022-2027, the market is also expanding as a result of the rising demand for discovering genetic disorders in the prenatal and neonatal population.
  • A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Pre-pregnancy Genetic Testing Market Report.

Pre-pregnancy Genetic Testing Market, Revenue Share - By Geography (%) for 2021

Pre-pregnancy Genetic Testing Market
For more details on this report - Request for Sample

Pre-pregnancy Genetic Testing Market Segment Analysis- By Test Type

The Pre-pregnancy Genetic Testing market based on test type can be further segmented into Diagnostic Test, Chorionic Villi Sampling (CVS), Transabdominal CVS, Transvaginal CVS, Amniocentesis, Placental Biopsy, Cordocentesis, Foetal Biopsy, Screening Test, Carrier Screening, Sequential Screening, and Maternal Serum Quad Screening. In 2021, the screening test sector of the worldwide pre-pregnancy genetic testing market had a commanding lead over the rest of the industry. This is owing to an increase in the number of screening procedures performed on pregnant women during delivery. In addition, an increase in family knowledge of genetic birth abnormalities, along with early detection of genetic disorders, is expected to boost the industry outlook in the next years. Furthermore, the screening test segment of the pre-pregnancy genetic testing market is expected to develop at the quickest rate, with a CAGR of 6.4% from 2022 to 2026, owing to technological improvements, an increase in the use of screening during pregnancy, and increased awareness of birth abnormalities. During and after pregnancy, screening tests are done to determine the presence of hereditary, congenital birth abnormalities. After 35 years of age, the risk of giving birth to a kid with chromosomal disorders increases, and the risk rises with age. The rising number of senior pregnancies will increase the demand for screening genetic tests. Technological developments in genetic screening procedures, such as non-invasive prenatal testing (NIPT), would channel the industry's growth even further.

Pre-pregnancy Genetic Testing Market Segment Analysis-By End Users

The Pre-pregnancy Genetic Testing market based on the end-users industry can be further segmented into Hospitals, Clinics, and Diagnostic Centers. The hospitals will have the most market share in 2021. This can be attributed to a growing trend in hospital settings for pre-pregnancy genetic testing. Parents and families have been putting a lot of emphasis on getting pre-pregnancy genetic testing done in government-funded hospitals that have all of the necessary capabilities for newborn screening. However, a slight increase in the number of screening programs in the healthcare setting suggests that the pre-pregnancy genetic testing market has a lot of room to develop. During the projection period 2022-2027, pertaining to the availability of current technology in pre-pregnancy genetic testing, as well as advantageous reimbursement regulations, the pre-pregnancy genetic testing market for hospitals is intended to create at the quickest rate, with a CAGR of 5.8%. The high use rate of prenatal and newborn genetic testing in hospitals is driving up demand for these healthcare facilities. Increasing government investment in hospitals, as well as an increase in the number of experienced and skilled experts, is boosting industry demand. In addition, attributed to the increasing number of births in hospitals and the availability of newborn genetic testing, pre-pregnancy genetic testing is becoming more popular. In the shortest amount of time, hospitals can provide genetic testing services.

Pre-pregnancy Genetic Testing Market Segment Analysis- By Geography

The Pre-pregnancy Genetic Testing market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. In 2021, North America has traditionally dominated the global pre-pregnancy genetic testing market with a market share of 36%. This geographical market has been spurred by North America's modern healthcare infrastructure and customers' high spending power, which allows them to access pricey medical services. North America is also a major hub for medical research, including efforts to make pre-pregnancy genetic testing more widely available and affordable. This has made incorporating technological advancements into the current healthcare scenario easier, propelling the regional pre-pregnancy genetic testing market forward. In 2021, the U.S. dominated the North American pre-pregnancy genetic testing market, and it is expected to continue to grow at a similar rate. The lion's share of revenue is owing to a number of variables, including the high prevalence of genetic illnesses and the growing demand for minimally invasive genetic testing across the country. According to the Centres for Disease Control and Prevention (CDC), around 6,000 newborns are born in the U.S. each year with Down's syndrome, which affects at least one out of every 700 babies. Pregnancy in later life, i.e. after 35 years, is on the rise, raising the risk of giving birth to a child with genetic abnormalities. Over 80% of children with trisomy 21 or Down's syndrome are born to women who are over 35 years old. These negative events, together with an increase in other genetic characteristics, are expected to increase public acceptance of pre-pregnancy genetic testing in the U.S.

Pre-pregnancy Genetic Testing Market Drivers

The market value of pre-pregnancy genetic testing is being driven by the rising pervasiveness of genetic disorders and chromosomal abnormalities.

In recent years, the prevalence of genetic illnesses and chromosomal anomalies has risen quickly over the world. Around 350 million people around the world suffer from different inherited and uncommon diseases. According to the World Health Organization (WHO), around 2 to 5% of live infants had genetic diseases or chromosomal abnormalities in 2019. In affluent economies, these illnesses account for roughly 30 percent of pediatric hospital visits and 50 percent of pediatric fatalities. As the prevalence of these ailments rises, so will the market's target demographic, signaling the industry's development. Disease load is increased by genetic and congenital disorders, which result in considerable mortality in pregnancy and newborn babies. In the United Arab Emirates, Bahrain, Oman, and Qatar, chromosomal abnormalities are one of the top causes of newborn mortality. Several studies conducted in Saudi Arabia suggest that congenital abnormalities are to blame for the majority of prenatal deaths. Furthermore, genetic and chromosomal disorders are responsible for a variety of disabilities, including mental retardation, blindness, and deafness. Similarly, genetic illnesses and chromosomal abnormalities are found in 25-60 per 1,000 births in India and are one of the primary causes of child mortality. Inheritable cardiovascular diseases are on the rise in many countries, thanks to genetic factors that increase the occurrence of complex conditions. During the projected period, the prevalence of chromosomal abnormalities, related diseases, and genetic disorders would intensify the pre-pregnancy genetic testing market size.

The market would be boosted by increasing technological developments in pre-pregnancy genetic screening.

The improved living standards of the worldwide population has resulted in a growing awareness among expectant parents regarding genetic disorders and the possibility of early detection. The rising inclination among urban parents to delay childbearing, as well as the higher average age of mothers, have all contributed to the need for pre-pregnancy genetic testing. In the last few decades, along with growing knowledge, the number of parents who can afford complete pre-pregnancy genetic testing has also expanded significantly. As a result of these considerations, the demand for pre-pregnancy genetic testing is increasing. The testing techniques have also become more reliable and convenient as a result of technological advancements in genetic testing equipment and procedures. The global market has benefited from the improved convenience of sophisticated pre-pregnancy genetic testing, as the rising preference for minimally invasive medical treatments has increased the demand for modern pre-pregnancy genetic testing. The market for pre-pregnancy genetic testing has benefited from rising healthcare spending in developing economies.

Pre-pregnancy Genetic Testing Market Challenges

High costs of the pre-pregnancy genetic tests are to limit the adoption and hence, hamper the market growth.

The expensive cost of a pre-pregnancy genetic test is causing poor uptake and affordability in many developing nations, which is posing a threat to market growth. Furthermore, in emerging countries, there is a dearth of public understanding about the dangers of genetic anomalies, which will stymie growth. At the same time, decreasing per capita healthcare spending and a lack of suitable test reimbursement regulations are two other variables that could slow growth. Major participants, on the other hand, place a premium on strategic activities such as alliances, acquisitions, new product launches, and commercialization for market growth. Furthermore, these companies spend a lot of money on research and development, which allows them to produce new goods and make a lot of money.

Pre-pregnancy Genetic Testing Industry Outlook:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Pre-pregnancy Genetic Testing Market. The top 10- Pre-pregnancy Genetic Testing Market companies’ are-

  1. Illumina, Inc.
  2. Sequenom Laboratories
  3. Natera, Inc.
  4. BGI Health
  5. Ariosa Diagnostics Inc.
  6. Natera and LifeCode
  7. Abbott Laboratories
  8. BioRad Laboratories Inc.
  9. F Hoffmann-La Roche
  10. Laboratory Corporation of America

Recent Developments:

  • In July 2021, Pacific Biosciences entered into a merger to acquire Omniome. This merger is poised to expand the market opportunities for sequencing in innovative ways that will add value to customers.
  • In March 2020, Agilent introduced Agilent GenetiSure Cyto microarrays that include three novel microarrays to meet the requirements of institutions and laboratories engaged in prenatal and postnatal research. This launch helped the company to gain a competitive advantage and strengthen its industrial position.
  • In June 2019, Invitae Corporation announced it has entered into a definitive agreement to acquire Singular Bio, Inc., a privately held company developing single-molecule detection technology that enables lower costs and expanded use of high-quality, cell-free, nucleic acid analysis, initially for application in non-invasive pre-pregnancy screening (NIPS).

Relevant Titles:

Genetic Testing Market - Forecast(2022 - 2027)
Report Code- HCR 0084

Infant Formula Testing Market - Forecast(2022 - 2027)
Report Code: FBR 0118

Digital Pregnancy Test Kit Market - Forecast(2022 - 2027) 
Report Code: HCR 64881

For more Lifesciences and Healthcare related reports, please click here

1. Pre-pregnancy Genetic Testing Market - Overview
    1.1 Definitions and Scope
2. Pre-pregnancy Genetic Testing Market - Executive Summary
3. Pre-pregnancy Genetic Testing Market - Landscape
    3.1 Market Share Analysis- Key Companies
    3.2 Company Benchmarking- Key Companies
    3.3 Financial Analysis - Key Companies
    3.4 Patent Analysis - Global
    3.5 Pricing Analysis - Average Price
4. Pre-pregnancy Genetic Testing Market - Startup companies Scenario Premium Premium
    4.1 Key startup company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Pre-pregnancy Genetic Testing Market - Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of successful ventures
6. Pre-pregnancy Genetic Testing Market - Forces
    6.1  Market Drivers
    6.2  Market Constraints/Challenges
    6.3  Porters Five Force Model
        6.3.1 Bargaining Power of Suppliers
        6.3.2 Bargaining Powers of Customers
        6.3.3 Threat of New Entrants
        6.3.4 Rivalry Among Existing Players
        6.3.5 Threat of Substitutes
7. Pre-pregnancy Genetic Testing Market - Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Pre-pregnancy Genetic Testing Market- By Test Type
    8.1 Diagnostic Test
    8.2 Chorionic Villi Sampling (CVS)
    8.3 Trans abdominal CVS
    8.4 Transvaginal CVS
    8.5 Amniocentesis
    8.6 Placental Biopsy
    8.7 Cordocentesis
    8.8 Fetal Biopsy
    8.9 Screening Test
    8.10 Carrier Screening
    8.11 Sequential Screening
    8.12 Maternal Serum Quad Screening
    8.13 Others
9. Pre-pregnancy Genetic Testing Market- By End -Users
    9.1 Hospitals
    9.2 Clinics
    9.3 Diagnostic Centers
10. Pre-pregnancy Genetic Testing Market- By Geography 
    10.1 North America
        10.1.1 U.S.
        10.1.2 Canada
        10.1.3 Mexico
    10.2 Europe
        10.2.1 U.K.
        10.2.2 Germany
        10.2.3 Italy
        10.2.4 France
        10.2.5 Spain
        10.2.6 Russia
        10.2.7 Rest of Europe
    10.3 Asia-Pacific
        10.3.1 China
        10.3.2 Australia
        10.3.3 Japan
        10.3.4 South Korea
        10.3.5 India
        10.3.6 Rest of Asia-Pacific
    10.4 South America
        10.4.1 Brazil
        10.4.2 Argentina
        10.4.3 Chile
        10.4.4 Colombia
        10.4.5 Others
    10.5 Rest of the World
        10.5.1 Middle East
        10.5.2 Africa
11. Pre-pregnancy Genetic Testing Market Entropy
12. Pre-pregnancy Genetic Testing Market- Industry/Segment Competition landscape Premium Premium
    12.1 Market Share Analysis
        12.1.1 Market Share by Country- Key companies
        12.1.2 Market Share by Region- Key companies
        12.1.3 Market Share at Global Level- Key companies
    12.2 Competition Matrix
    12.3 Best Practices for Companies
13. Pre-pregnancy Genetic Testing Market- Key Company List by Country Premium Premium
14. Pre-pregnancy Genetic Testing Market Company Analysis
    14.1 Company 1
    14.2 Company 2
    14.3 Company 3
    14.4 Company 4
    14.5 Company 5
    14.6 Company 6
    14.7 Company 7
    14.8 Company 8
    14.9 Company 9
    14.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.